CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting

Tyrosine kinase inhibitors (TKIs) are highly effective for the treatment of chronic myeloid leukemia (CML), but very few patients are cured. The major drawbacks regarding TKIs are their low efficacy in eradicating the leukemic stem cells responsible for disease maintenance and relapse upon drug cess...

Descripción completa

Detalles Bibliográficos
Autores principales: Landberg, Niklas, von Palffy, Sofia, Askmyr, Maria, Lilljebjörn, Henrik, Sandén, Carl, Rissler, Marianne, Mustjoki, Satu, Hjorth-Hansen, Henrik, Richter, Johan, Ågerstam, Helena, Järås, Marcus, Fioretos, Thoas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830390/
https://www.ncbi.nlm.nih.gov/pubmed/29284680
http://dx.doi.org/10.3324/haematol.2017.169946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830390/
https://www.ncbi.nlm.nih.gov/pubmed/29284680
http://dx.doi.org/10.3324/haematol.2017.169946

Ejemplares similares